NanoVibronix receives Nasdaq equity deficiency notice; equity of $1.872M below $2.5M minimum

ENvue Medical, Inc.

On Nov 19, 2024, Nasdaq notified NanoVibronix it failed the $2.5M stockholders' equity rule based on $1.872M as of Sep 30, 2024.
This adds to an existing bid price deficiency; both will be considered at the upcoming Nasdaq Hearings Panel hearing.
The Company will present a compliance plan and request an extension, but continued listing is not assured.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.